Podcasts about Acute lymphoblastic leukemia

Maribeth Ditmars has suffered plenty of heartache and loss for the past 25 years, beginning with the diagnosis of Acute Lymphoblastic Leukemia in 1997 and the subsequent passing of her son Christopher at the age of 14 in 2001. This was followed by the passing of her younger son Jarrod when he was 21 years old from an accident on July 4th of 2015, which left him unconscious for the last 4 days of his life. In between those years, Maribeth successfully battled her own demons with her dependence on alcohol, to the point where she has been able to counsel many people who have had similar problems and she is now very involved in helping others. Maribeth has now been sober for 22 years . 

During Alisha Harper's pregnancy, she was told that there was a 60 percent chance that her son would be born with Down Syndrome. That statement turned out to be a correct one as Chase was born in December of 2016 with this illness and by the time Chase was 4 years old, Alisha saw that his Down Syndrome was manageable. One month after feeling as good as possible about how Chase was doing, he developed a body rash which turned out to be a symptom of Acute Lymphoblastic Leukemia. Despite having this 1-2 punch thrown at him, Chase is doing well as he is now 9 years old and living his best life possible. 

10 year old Charli Martin hurt her shoulder while competing in the New York State School Wrestling Tournament when she was in 5th grade in 2023. While going for Physical Therapy, Charli noticed a lump on her neck and after taking antibiotics and still in therapy, the pain in her shoulder did not go away. Charli then had this lump biopsied and the result was her diagnosis of High Risk B Cell Acute Lymphoblastic Leukemia. Charli has now completed her 8th grade year and at 13 years of age is back playing sports and living the life of a normal and healthy 13 year old teenager.  

Sydney Belsher has been through a great deal in her still very young life as she is 12 1/2 years old, which started with stomach issues almost from her birth in the fall of 2013, and then her diagnosis of Infantile Acute Lymphoblastic Leukemia which came when she was 6 months old in April of 2014. Right after her diagnosis Sydney's lifespan was very uncertain as her doctors feared she would have a stroke and may not survive. This did not happen thankfully but Sydney has battled both physical and mental issues over the years . Fortunately Sydney has survived all of her issues and is trying to live her best life possible.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QKH865. CME/MOC/AAPA credit will be available until May 13, 2027.Expanding Bispecific Options for Acute Lymphoblastic Leukemia: From Current Standards to Future Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QKH865. CME/MOC/AAPA credit will be available until May 13, 2027.Expanding Bispecific Options for Acute Lymphoblastic Leukemia: From Current Standards to Future Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QKH865. CME/MOC/AAPA credit will be available until May 13, 2027.Expanding Bispecific Options for Acute Lymphoblastic Leukemia: From Current Standards to Future Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QKH865. CME/MOC/AAPA credit will be available until May 13, 2027.Expanding Bispecific Options for Acute Lymphoblastic Leukemia: From Current Standards to Future Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QKH865. CME/MOC/AAPA credit will be available until May 13, 2027.Expanding Bispecific Options for Acute Lymphoblastic Leukemia: From Current Standards to Future Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QKH865. CME/MOC/AAPA credit will be available until May 13, 2027.Expanding Bispecific Options for Acute Lymphoblastic Leukemia: From Current Standards to Future Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QKH865. CME/MOC/AAPA credit will be available until May 13, 2027.Expanding Bispecific Options for Acute Lymphoblastic Leukemia: From Current Standards to Future Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QKH865. CME/MOC/AAPA credit will be available until May 13, 2027.Expanding Bispecific Options for Acute Lymphoblastic Leukemia: From Current Standards to Future Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

When she was 4 months old on November 14th of 2023, Kalia Arrayan was diagnosed with High Risk B Cell Acute Lymphoblastic Leukemia. This diagnosis came as a complete shock to her parents Heather and Casey who did not see any clear symptoms before a routine checkup showed a lump on her spleen. Kalia went through a very difficult treatment process for the next 8 months before she underwent a Bone Marrow Transplant with her 11 year old brother being her donor. Kalia has been doing much better over the past nearly two years as she approaches her 3rd birthday.

Marissa Metcalf does not remember many details from her treatment during her battle with Acute Lymphoblastic Leukemia which took place in 2010 when she was 3 1/2 years old. What she does know, now that she is 19 years old and looking at possible careers, is that this form of Pediatric Blood cancer has affected her in different ways as she approaches 20 years of age, and wants to help others who have been diagnosed with cancer by becoming an Oncology Nurse, which would be a great accomplishment for her and a good thing for her future patients.

Mason Fox was 10 years old when he was diagnosed with Acute Lymphoblastic Leukemia in April of 2023. Mason then went through treatment and was doing very well with his recovery before a Fungal infection got the best of him quickly in February of 2024, and led to his surprising and unfortunate passing, not even 10 full months past his original diagnosis. His parents Leslie and Michael detail the amazing persona that Mason had as he was most concerned with helping others even during treatment for this blood cancer, as he bought toys with his own money and would walk down the halls at St. Joseph's Children's Hospital with these toys in a wagon, hooked up to his IV pole, and would deliver them to the other Pediatric Cancer patients on his floor. 

A chance phone call between Amy Davis and a friend who was taking her daughter to get checked for allergies, led Amy to take her then 2 year and 10 month old daughter Phoebe to see her Pediatrician, where shortly thereafter she was diagnosed with Acute Lymphoblastic Leukemia in June of 2010. Phoebe was in Boston Children's Hospital for 8 weeks and completed her treatment as an outpatient for the next 26 months, until she was 5 years old. From that time on Phoebe has been cancer free with no long term side effects, and is feeling great as an 18 year old. It is always nice to talk about successful Pediatric Cancer journey's on this podcast. 

Amelia Mijach's then 2 year old son Hayes was diagnosed with High Risk Acute Lymphoblastic Leukemia when he was 2 years old in August of 2024 and the reason for his high risk status was because of his extraordinarily high white blood cell count at diagnosis. Hayes then contacted a serious fungal infection during his consolidation phase of his treatment and during the next year and a half of treatment he needed to fight off a battle of Neutropenic Fever and he experienced other battles as well. Finally in  December of 2025 Hayes turned the corner and is doing much better physically and is as active as possible. 

Marlise Luskin, MD With so many new advances in acute lymphoblastic leukemia (ALL), understanding today's treatment landscape can give patients a clearer, more hopeful outlook. In this episode, we speak with Marlise Luskin, MD of the Dana-Farber Cancer Institute, about what adults should know when facing a diagnosis of acute lymphoblastic leukemia. Dr. Luskin helps listeners understand how ALL develops, how subtypes are identified, and why genetics play an important role in guiding treatment. She discusses current therapies including chemotherapy, targeted agents and immunotherapies including CAR T-cell therapy, as well as how care teams monitor progress and manage side effects. While ALL is a complex disease, patients and caregivers will hear clear explanations, practical information, and meaningful reasons to feel hopeful about the advances shaping ALL care today. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: Acute lymphoblastic leukemia (ALL) Minimal/measurable residual disease (MRD) fact sheet Allogeneic stem cell transplantation Clinical Trial Support Center ALL Children and Teens booklet Additional Blood Cancer United Support Resources: Information Specialists Financial support Online Chat Free Nutrition Consultations Free telephone/web patient programs Free booklets Support groups Caregiver support Caregiver Workbook Young Adult Resources Survivorship Workbook Advocacy and Public Policy Patient Community Mental Health Resources Episode supported by Syndax Pharmaceuticals Inc. The post Acute Lymphoblastic Leukemia (ALL): The New Tools Shaping Tomorrow first appeared on The Bloodline with Blood Cancer United Podcast.

In today's episode, we welcomed Wendy Stock, MD, to discuss key recommendations from the ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults, which were published in February. Stock is the Anjuli Seth Nayak Professor of Medicine at University of Chicago Medicine and co-leader of the Clinical and Experimental Therapeutics research program at the University of Chicago Medicine Comprehensive Cancer Center in Illinois.In our exclusive interview, Dr Stock explained how specialists, including hematologists, adolescent/young adult (AYA) psychosocial care specialists, pharmacists, methodologists, and patient representatives, contributed to the formation of the ASH AYA ALL guidelines, discussed key recommendations in the guidelines supported by evidence, and detailed how these guidelines can aid in AYA ALL management.

Featuring an interview with Dr Bijal Shah, including the following topics: Advent and importance of blinatumomab in the therapeutic landscape of acute lymphoblastic leukemia (ALL) (0:00) Similarities and differences between bispecific T-cell engagers (BiTEs) and bispecific antibodies (5:51) Rationale underlying the development of surovatamig and MK-1045; benefits of blinatumomab for patients without detectable minimal residual disease (9:56) Extramedullary ALL, including in the CNS (13:32) Key principles in the development and use of surovatamig and MK-1045, including structural features and recent efficacy and safety findings (18:34) Ongoing immunotherapy trials for ALL, including studies of BiTEs and chimeric antigen receptor T-cell therapy (25:37) Case: A woman in her late 50s with newly diagnosed Philadelphia chromosome-positive B-cell ALL and multiple comorbidities (31:48) Case: A woman in her early 50s with newly diagnosed B-cell ALL, a TP53 mutation and significant extramedullary disease including the CNS (41:16) Case: A man in his early 50s with intermediate-risk B-cell ALL who receives surovatamig on a clinical trial (53:05) CME information and select publications

Dr Bijal Shah from Moffitt Cancer Center in Tampa, Florida, discusses the role of BiTEs in the management of ALL.CME information and select publications here.

Featuring a slide presentation and related discussion from Dr Bijal Shah, including the following topics: Historical approaches to managing acute lymphoblastic leukemia, their limitations and present approaches to treatment (0:00) Mechanistic approach underlying blinatumomab; key clinical trial data and their implications (7:29) Mechanistic approaches underlying surovatamig and MK-1045; dosing and administration strategies with various bispecific T-cell engagers (23:27) Key clinical trial data with surovatamig; implications for practice (32:38) Key clinical trial data with MK-1045; implications for practice (39:02) Synthesizing and comparing data across subcutaneous blinatumomab, surovatamig and MK-1045 (42:36) CME information and select publications

In this episode, Dr Ibrahim Aldoss and Dr Bijal Shah discuss how immunotherapy has transformed the treatment landscape of acute lymphoblastic leukemia (ALL), particularly in relapsed/refractory B-cell ALL, including: CD19-directed CAR T-cell therapies Next-generation CD19 bispecific antibodies The evolving role of allogeneic transplant Presenters: Ibrahim Aldoss, MD Associate Professor Division of Leukemia Department of Hematology/HCT City of Hope National Medical Center Duarte, California Bijal Shah, MD, MS Senior Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, Florida Link to full program: https://bit.ly/4cRjiUi Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Sydney Leandro was 5 years old on Easter Sunday of 2020 when she was diagnosed with Acute Lymphoblastic Leukemia. Now at age 11, Sydney is feeling and doing well and is able to live a good life. In 2025 her brother Jack, who is now 9 years old, decided to start a non-profit called PUCKS FOR BUCKS in which he shot approximately 200 pucks a day from his driveway into a hockey goal and raised $1.00 for each puck he shot, which he donated in Sydney's honor and to help other Pediatric Cancer Patients. He donated this money to the A Wish Come True Non- Profit which had treated the Leandro family to a trip to San Diego in 2023. Jack will continue his non profit after his current hockey season ends and will begin from where he left off last summer in which he had totaled 10,027 pucks shot.

Tara Daniels is now 33 years old , married, working at a job that she enjoys , and living as good of a life as she can. Back in 2009 when Tara was 16 years old this was not the case as she was diagnosed with Acute Lymphoblastic Leukemia . Tara relapsed twice, with the last relapse coming in 2016. Tara then received a Bone Marrow transplant and since that time period, she has been cancer free. Tara will talk about all that she has been through, including survivorship on today's podcast.

Gabriella and Nicholas are 22 years old, and about to graduate from Purdue University and Indiana University respectively. This fall they will enter Medical School and will likely pursue careers in the medical field that will concentrate on Pediatric Cancer. Their cousin Maddox is now 14 years and well past his battle with Acute Lymphoblastic Leukemia but Maddox's sister Maia, who was diagnosed with Ewings Sarcoma in 2022 when she was 6 years old, passed away from this Bone Cancer on November 2nd of 2025. Gabriella and Nicholas will talk about what Maia went through during her cancer battle and will also talk about their amazing Strides For Sarcoma Non-Profit which they started after Maia relapsed, which shows both their dedication to Maia and their dedication to doing what they can to help eradicate the disease that Maia was forced to go through.

4 year old Ava Blazis woke up on the morning of March 11th 2023 with a very unusual pain in her abdomen which continued to get worse as the day wore on. Her mother Angela brought her to UMass Memorial Medical Center and 3 days later on March 14th, she was diagnosed with Acute Lymphoblastic Leukemia. Angela and Ava then spent the next 65 days at Boston Children's Hospital while Ava was undergoing treatment. Meanwhile Angela's sister Johanna Annuziata got busy with helping to look after Ava's brother Michael, and also helping to start Team Ava, an unofficial Non-Profit, which has already raised over $300,000 to help in the cause of Pediatric Cancer. Ava is now 7 years old and is doing well physically as she has been in remission since May of 2025. 

In this week's episode, Blood Associate editor Dr. Hervé Dombret interviews authors Drs. Sarah K. Tasian and David T. Teachey on their contributions to the How I Treat Series on acute lymphoblastic leukemia. Dr. Tasian's paper, “How I treat Philadelphia chromosome-like acute lymphoblastic leukemia in children, adolescents, and young adults” discusses the different classes of Ph-like ALL and reviews the recent trials investigating TKIs and immunotherapy specifically for this high-risk patient population. Dr. Teachey's paper, “How I treat ETP-ALL in children”, discusses the best current and emerging therapies that may be used in patients with ETP ALL, including nelarabine and other new agents, immunotherapy, and allogeneic HSCT.See the full How I Treat series in volume 145 issue 1 of Blood.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH information, and to apply for credit, please visit us at PeerView.com/AEN865. CME/MOC/EBAH credit will be available until January 4, 2027.Moving Forward in B-ALL: Insights on Modern and Emerging Standards With Off-the-Shelf Bispecific Antibodies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Lymphoblastic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH information, and to apply for credit, please visit us at PeerView.com/AEN865. CME/MOC/EBAH credit will be available until January 4, 2027.Moving Forward in B-ALL: Insights on Modern and Emerging Standards With Off-the-Shelf Bispecific Antibodies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Lymphoblastic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH information, and to apply for credit, please visit us at PeerView.com/AEN865. CME/MOC/EBAH credit will be available until January 4, 2027.Moving Forward in B-ALL: Insights on Modern and Emerging Standards With Off-the-Shelf Bispecific Antibodies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Lymphoblastic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH information, and to apply for credit, please visit us at PeerView.com/AEN865. CME/MOC/EBAH credit will be available until January 4, 2027.Moving Forward in B-ALL: Insights on Modern and Emerging Standards With Off-the-Shelf Bispecific Antibodies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Lymphoblastic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

Caitlin White's son Grant was 2 years old when he complained of pain from his thumb in November of 2022. This pain was not taken seriously enough by his doctors, one of whom looked at Grant while he was lying on the floor and gasping for breath in the hospital waiting room and said that his "shift was almost over" and he would order him a prescription, which had been the supposed solution heard too many time before by Caitlin. Caitlin then demanded a change in doctors, receiving a new female doctor, and this led to Grant finally being diagnosed properly for Leukemia, and began his treatment almost immediately.

Chad Gordon radiated positivity when talking about his daughter Adley's successful battle with B Cell Acute Lymphoblastic Leukemia which began just before her 2nd birthday in  February of 2022, and ended 800 days later when she was able to Ring the Bell at Penn State's Hersey Children's Hospital. Chad talks about what Adley went through, and also how the THON event which is a very well known Dance Marathon at Penn State, and the Four Diamonds Childhood Cancer Organization did so much to help Adley and the Gordon Family.

Even though it made perfect sense that 2 year old Waylynn McCullough was experiencing the same cold like symptoms that her dad Kevin and her mom Logan had already been through, Waylynn was not as fortunate to say the least, as what she was experiencing was her lead up to her High Risk B Cell Acute Lymphoblastic Leukemia diagnosis which was given to her in January of 2024. Waylynn is now 4 1/2 years old and has been through a very difficult initial treatment plan which was followed by a very difficult Delayed Intensification Treatment plan. Waylynn is now feeling well and thankfully is leading the life for the most part as a very healthy 4 1/2 year old girl. 

    When she began experiencing severe bruising and fatigue and turning pale in late 2013, Casey Kang sought medical attention.  This led to a diagnosis of acute lymphoblastic leukemia.  She was placed on an aggressive, 18-month chemotherapy regimen, which included doxorubicin and methotrexate.  Casey relapsed three times during which she was placed on an experimental immunotherapy.  All told, she spent 168 days in a hospital, but Casey achieved survivorship.  She is now a coach who helps women diagnosed with cancer through the physical, mental and emotional challenges that occur after treatment.   When Casey Kang experienced various aches and pains at the end of 2013, she thought they were tied to holiday- or work-related stress.  She sought medical attention, was prescribed ten days of antibiotics, and was told to return in two weeks.  During the ten days, things got worse.  She was stricken with extreme fatigue, bruising, vision issues and her turning pale.  While this went on, she continued to go to work.  She underwent blood tests, and they revealed she had leukemia.  Even before the test results came back, her care team called for a bone marrow transplant, so sure were they that she had cancer.   Casey said her cancer was subsequently diagnosed as acute lymphoblastic leukemia.  Because of its aggressive nature, she was put on an aggressive, 18-month chemotherapy regimen.  It included doxorubicin and methotrexate.  She experienced two relapses and was prescribed an experimental immunotherapy.   Multiple hospital stays totaled 168 days.  During that time, Casey learned how mentally tough she was and is.  As much as she disliked the time in the hospital, she was sure to create a routine that would get her through the day.  Casey used the hospital floor's exercise bike and walked laps around the floors, with 17 laps equaling a mile.   Despite a grueling journey, Casey Kang achieved survivorship.  She is active on social media, as she works tirelessly to aid woman diagnosed with cancer to make them physically, mentally and emotionally strong when dealing with life after treatment.  As for herself, she says her overall is better than it was before her diagnosis.   Additional Resources:   Casey's Website:   https://www.thehappierhustle.com   Casey's Free Guide:   https://casey-head.mykajabi.com/free-guide          

After surviving her childhood fight with Acute Lymphoblastic Leukemia, Claire Galvin has gone on to have an outstanding academic career, which has included holding a double major in Biology and Psychology which led to her receiving an Honors Bachelor Degree from the University of Toronto, a Master of Science Degree in Experimental Medicine from the University of British Columbia, and is now pursuing her Doctorate in Clinical Psychology from Concordia University in Montreal. Clair is currently working on her Dissertation which involves the study of Pediatric Cancer survivors and how they have transitioned into adulthood. Claire's dissertation is called the CHILDHOOD CANCER IDENTITY PROJECT. If you are interested in participating in this project then please email Claire at cchip.research@gmail.com

Alex Lynch was diagnosed with Acute Lymphoblastic Leukemia , which came with  2 very rare genetic markers which only 2 percent of ALL kids have had to deal with. Alex's diagnosis came in May of this year and he is now in his consolidation stage. Alex and his mom Yuliya will talk about what Alex has been through and what his treatment future might hold. They will also talk about Alex's 6 sibling's who range in age from 2 months to 14 years .  If you would like to see how Alex is doing and hopefully send him a message of encouragement, please contact him at https://www.facebook.com/groups/alexlynch/    

In this Review Series episode, Associate Editor Dr. Hervé Dombret speaks with Dr. Mark Litzow about the latest immunotherapy advances for Acute Lymphoblastic Leukemia (ALL). The discussion highlights innovative treatments like blinatumomab and inotuzumab, which are showing remarkable success in clinical trials, including an 85% three-year survival rate and over 90% complete remission in elderly patients. Researchers are focusing on reducing chemotherapy intensity, developing personalized treatment approaches, and identifying optimal immunotherapy strategies for different ALL subtypes. The conversation underscores a promising shift towards more targeted, less toxic treatments that could significantly improve patient outcomes across various age groups and disease characteristics. These emerging therapies represent a potential paradigm shift in ALL treatment, offering hope for more effective and less aggressive therapeutic interventions.Read Dr. Litzow's paper “Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia” or find the whole review series on acute lymphoblastic leukemia in volume 145 issue 14 of Blood Journal. 

In this episode, we talk with Deb Brandt, caregiver to her husband, JR, a survivor of Philadelphia-positive acute lymphoblastic leukemia (ALL). Deb shares the journey that began in September 2016 when JR noticed unusual symptoms that led to an urgent diagnosis. Within days, he began an aggressive chemotherapy regimen, with the hope of a bone marrow transplant as the only cure. The search for a match took seven months, eventually expanding internationally until a 10/10 donor was found, leading them to relocate to Stanford University for the procedure.We discuss the practical realities of caregiving, especially the financial side. Deb emphasizes connecting early with medical teams, social workers, nurse navigators, and financial departments. She details how they tapped into resources from organizations like the Leukemia & Lymphoma Society, utilized a GoFundMe campaign, applied for Social Security disability benefits through its "blue book" criteria, and discovered that many medical bills are negotiable. Deb highlights pharmaceutical assistance programs, including the Medicine Assistance Tool (MAT), NeedyMeds, and Triage Cancer, which help patients access affordable medication.Deb also shares the importance of proactive communication with insurance providers, especially when facing financial hardship, and leveraging housing support networks such as Ronald McDonald House and Hope Lodge when treatment requires relocation. Don't be afraid to use your personal network, too!On the emotional side, Deb describes how caregiving is deeply personal, with strategies unique to each person. She and JR found joy in music, storytelling, birdwatching, and creating comforting hospital environments. She underscores the need for caregivers to take their own breaks — whether walks, massages, or naps — and the value of long-term follow-up care, especially when complications like chronic graft-versus-host disease arise.We explore life after transplant, the strengthening of family bonds, and Deb's practical lesson of “learning the job” by taking over JR's household roles. Professionally, Deb works in Montana's vocational rehabilitation department, helping people with disabilities — including those recovering from cancer — re-enter or adapt to the workforce. She shares that similar resources are available in every U.S. state.Deb's closing message is about consciously choosing hope. She encourages caregivers and patients to find daily glimmers of light, allow space for tears, but always return to gratitude and positivity. JR is now eight years post-transplant, living with ongoing health challenges but embodying resilience and determination.This season is sponsored by Sanofi: https://www.sanofi.com/And Jazz Pharmaceuticals: https://www.jazzpharma.com/Check out JR's Survivor Story from Season 14 here: https://marrowmasters.simplecast.com/episodes/jr-brandtAdditional Resources:Leukemia & Lymphoma Society (LLS) is now Blood Cancer United: https://bloodcancerunited.org/Be The Match – https://bethematch.orgMedicine Assistance Tool (MAT) – https://medicineassistancetool.orgNeedyMeds – https://www.needymeds.orgTriage Cancer – https://triagecancer.orgRonald McDonald House Charities – https://rmhc.orgHope Lodge – https://www.cancer.org/support-programs-and-services/patient-lodging/hope-lodge.htmlVocational Rehabilitation Services Directory – Search “[Your State] vocational rehabilitation” National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Kailyn Thelen has health issues of her own, which do not include any type of cancer, and still is able to run her own non-profit which concentrates on making blankets for children with pediatric cancer and other diseases. Kailyn met Ali Herbert when she was just 2 months away from passing away from her battle with Very High Risk Acute Lymphoblastic Leukemia, which happened on November 29th of 2020, the same day as her mom Heather's birthday. Kailyn will talk about Ali and about what she does to help others, as she is dealing with her own health issues.

After recovering from her battle with Acute Lymphoblastic Leukemia in the late 1990's Shannon Hartey had a number of late effects that bothered her until 2020. By that time Shannon was in her early 30's  and these late effects got so bad, that Shannon was unable to know from day to day whether the intense  pain level that she was receiving in her head for a variety of reasons  combined with other cognitive issues that can happen to her at any time , will allow her to have even a normal day. The alternative, which happens regularly, takes her to a health level that is so difficult, it can make her life totally miserable on many levels. What Shannon has been diagnosed with, all because of her treatment for ALL which she received after this form of Pediatric Blood Cancer was discovered when she was 6 years old in 1994, is known as SMART SYNDROME. These late effects are almost totally unheard of, and have been very difficult for some of the best oncologists and doctors to have an answer for. 

In this week's episode, we'll learn more about how exogenous CD19 stimulation affects CAR T-cell persistence in B-cell acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy; new algorithms that incorporate sequential rapid immune-assays, intended to improve diagnosis of heparin-induced thrombocytopenia, and resource-adaptive survival prediction models to help guide management of patients with chronic myelomonocytic leukemia.Featured Articles:Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALLSequential combinations of rapid immunoassays for prompt recognition of heparin-induced thrombocytopeniaBLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia

In this episode, we review the high-yield topic ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Acute Lymphoblastic Leukemia (ALL) ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Oncology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings.Program Abstracts: POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCLECHO: Rituximab-Bendamustine ± Acalabrutinib in Untreated High-Risk MCLCADANCE-101: BGB-16673 BTK Degrader in R/R CLL/SLLInMIND: Tafasitamab, Lenalidomide, Rituximab in R/R FLSHR2554: Oral EZH2 Inhibitor in R/R PTCLSYRUS: AZD0486 Bispecific Antibody for R/R B-ALLPresenters:Max S. Topp, MDHead of Hematology and Clinical CAR-T Program LeadAssociated ProfessorMedinische Klinik und Poliklinkik IIUniversity of WurzburgWurzburg, GermanyPier Luigi Zinzani, MD, PhDProfessor of HematologyAlma Mater Studiorum- University of BolognaHead, “Seràgnoli” Institute of HematologyIRCCS Azienda Ospedaliero-Universitaria di BolognaDepartment of Medical and Surgical SciencesBologna University School of MedicineBologna, ItalyLink to full program:https://bit.ly/4obcJPI

Gisela Chavez's then 4 year old daughter Arianny was experiencing flu like symptoms during the 2024 Christmas season and finally after her fever spiked to the 104-105 range Gisela took Arianny to Advovcate Children's Hospital not too far from Chicago, where she was diagnosed with Acute Lymphoblastic Leukemia. Arianny's diagnosis was given just after her 5th birthday in January of this year, and she has completed 6 months out of a treatment protocol that still has 2 years to go. 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/VFF865. CME/MOC credit will be available until July 4, 2026.ALL-in on Bispecific Innovation: Guidance on the Present and Future of Off-the-Shelf Immunotherapy in Acute Lymphoblastic Leukemia In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

Cedar Connell was 15 years old when he found himself on his way to Lurie Children's Hospital in Chicago to begin his treatment for B Cell Acute Lymphoblastic Leukemia in 2022. Cedar and his mom Kiki will talk about the difficult treatment that he went through, including his move from Chicago to the Dana Farber Cancer Institute in Boston in 2023. Cedar is now getting ready to do his part for the Leukemia and Lymphoma Society as TEAM CONNELLSLLS will be getting ready for a 31 day challenge beginning on July 1st and ending on August 1st to exercise 3 miles each day for that time period, in the hope that they raise 35,000.

Alexandra Wilson passed away just 10 months after being diagnosed with Acute Lymphoblastic Leukemia in March of 2002, from this Blood Cancer that normally has a very high cure rate. Her twin sister Arianna will talk about her sister and about her role as the now official Executive Director of the Alex's Team Foundation which was named in Alexandra's honor, and helps in many ways the cause of Pediatric Cancer, with an emphasis on the Pediatric Cancer Nursing Community. 

The normal protocol for a diagnosis of Acute Lymphoblastic Leukemia is around 2 years of treatment but Lorie Chartiers daughter Gracie, who was diagnosed with this form of Pediatric Blood cancer when she was turning 10 years old in 2016, did not have the luxury of a normal maintenance program during her recovery. For the past 6 years leading up to 2025, she has struggled with many post treatment side effects which have hampered her, especially from a psychosocial point of view. Now 18 years old, Gracie is doing what she can to lead her best life possible.